Stay-At-Home Stocks Sell Off On Vaccine News
Michael Kramer | Nov 10, 2020 01:02AM ET
Yesterday started strong but failed to close in the same manner in which it started. The S&P 500 surged by more than 3% on Pfizer's (NYSE:PFE)’s positive news that its COVID vaccine had 90% efficacy, which is amazing. It happens to be much better than anyone expected.
S&P 500
However, the index gave back nearly all of those gains by days end, finishing higher by around just 1.1%, while the Nasdaq 100 QQQ ETF fell by over 2%. I hate to say it, but the vaccine’s news may serve as a selling event. It triggered a massive liquation across many of the technology names many people have grown to love. Many of these technology names are extremely overvalued, which means they can fall a lot before people step in and start repurchasing them. Just consider that.
The S&P 500 gapped higher to start the day but began to fill the gap by days end. It would need to fall back to 3,520 to fill it. I really don’t see a reason why the S&P 500 can’t fall back to 3,310 over the next few days to a week. The vaccine news is great, and no one is more excited than I am, but let’s face facts, there is still plenty of time for that.
NASDAQ
Meanwhile, I think the selling action is just getting going in the QQQ With a vaccine coming down the road, the market will need to reprice all of these technology stocks. Nobody thought Pfizer’s vaccine would be this successful. That means while many of these stocks have a really bright future, it may not be bright enough to justify some valuations.
Additionally, it isn’t likely that the financial sector will rise by almost 8% every day, and the energy sector will jump by over 14% to offset the declines in technology.
Zoom
Like take Zoom, the stock fell 17.7%, and it is trading for 36 times 2023 sales estimates. Hey, that’s a lot by anyone’s standard. Maybe it fills the gap higher and goes back to $504, but then again, if it goes below $408, it will probably be $325. The RSI doesn’t even have it oversold yet.
Get The News You Want
Shopify
Shopify (NYSE:SHOP) trades for 21.6 times 2023 sales estimates, a bargain compared to Zoom. Great business, a great prospect for the future. Probably should trade for a lower multiple, though. A drop below $910 sets up that drop to $850, which sets up a drop to $740.
Square
Square, with its $83 billion market cap, and trades with a 2022 PE ratio of 101.5, and 2022 EV/EBITDA ratio of 75, and a 2022 PEG ratio of 3.6. Again, a great company, a bright future, just very, very expensive. I wouldn’t be surprised if this were back at $162 fairly soon.
NVIDIA
NVIDIA (NASDAQ:NVDA), which trades for 44.5 times 2023 earnings estimates, a price to sales ratio of 16, and a lot of dilution coming to buy ARM. Again, a great future, but it doesn’t mean the stock isn’t expensive; it absolutely is beyond expensive for a chip company. So if it breaks the uptrend for a second time, is there a good chance it goes back to $460, probably.
Exxon
Exxon (NYSE:XOM) had a great day. I guess people will be driving a little more if you get a vaccine. Now that Exxon rose and Zoom fell, Exxon’s market cap has passed Zoom once again. Imagine that.
Original Post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.